The prognostic value of C-reactive protein in renal cell carcinoma: A systematic review and meta-analysis

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 50.e1-50.e8

  Hu, Qingfeng ^a   Gou, Yuancheng ^a   Sun, Chuanyu ^a   Ding, Weihong ^a   Xu, Ke ^a   Gu, Bin ^a   Xia, Guowei ^a   Ding, Qiang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

C reactive protein; Meta analysis; Prognosis; Renal cancer

Indexed keywords

C REACTIVE PROTEIN;

ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; DATA EXTRACTION; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SYSTEMATIC REVIEW;

C-REACTIVE PROTEIN; META-ANALYSIS; PROGNOSIS; RENAL CANCER;

C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS;

EID: 84890803006     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.07.016     Document Type: Article

References (38)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Delahunt B. Advances and controversies in grading and staging of renal cell carcinoma. Mod Pathol 2009, 22(Suppl. 2):S24-S36.
3. Moch H., Artibani W., Delahunt B., et al. Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol 2009, 56:636-643.
4. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting meta-analysis of observational studies in Epidemiology (MOOSE) group. J Am Med Assoc 2000, 283:2008-2012.
5. Ramsey S., Lamb G.W., Aitchison M., et al. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int 2008, 101:959-963.
6. Ito K., Asano T., Yoshii H., et al. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 2006, 13:1365-1370.
7. Miyata Y., Koga S., Nishikido M., et al. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 2001, 58:161-164.
8. Kawata N., Nagane Y., Yamaguchi K., et al. How do symptoms have an impact on the prognosis of renal cell carcinoma?. Int J Urol 2008, 15:299-303.
9. Ljungberg B., Grankvist K., Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997, 33:1794-1798.
10. Masuda H., Kurita Y., Suzuki A., et al. Prognostic factors for renal cell carcinoma a multivariate analysis of 320 cases. Int J Urol 1997, 4:247-253.
11. + memory T cells in renal cell carcinoma. Br J Cancer 2011, 105:1191-1196.
12. Komai Y., Saito K., Sakai K., et al. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 2007, 99:77-80.
13. Kai F., Takayama T., Sugiyama T., et al. Efficacy of adjuvant interferon-alpha therapy following curative resection in renal cell carcinoma: before the molecular targeting therapy era. Jpn J Clin Oncol 2009, 39:310-314.
14. Komura K., Inamoto T., Black P.C., et al. Prognostic significance of body mass index in Asian patients with localized renal cell carcinoma. Nutr Cancer 2011, 63:908-915.
15. Harada K., Miyake H., Kusuda Y., et al. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy. BJU Int 2012, 110:E1131-E1137.
16. Falkensammer C.E., Thurnher M., Leonhartsberger N., et al. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival. BJU Int 2011, 107:1893-1898.
17. Saito K., Tatokoro M., Fujii Y., et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 2009, 55:1145-1153.
18. Ramsey S., Lamb G.W., Aitchison M., et al. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007, 109:205-212.
19. Vogl U.M., Zehetgruber H., Dominkus M., et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 2006, 95:691-698.
20. Kume H., Kakutani S., Yamada Y., et al. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors?. J Urol 2011, 185:1611-1614.
21. Miyake H., Kurahashi T., Takenaka A., et al. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol 2009, 27:598-603.
22. Shinohara N., Abe T., Mochizuki T., et al. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era?. Urol Oncol 2011, [Epub ahead of print].
23. Fujita T., Iwamura M., Ishii D., et al. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol 2012, 19:908-913.
24. Ito K., Yoshii H., Sato A., et al. Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. J Urol 2011, 186:430-435.
25. Iimura Y., Saito K., Fujii Y., et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 2009, 181:1004-1012. [discussion 1012].
26. Bedke J., Chun F.K., Merseburger A., et al. Inflammatory prognostic markers in clear cell renal cell carcinoma-preoperative C-reactive protein does not improve predictive accuracy. BJU Int 2012, 110:E771-E777.
27. Kawai Y., Matsuyama H., Korenaga Y., et al. Preoperative erythrocyte sedimentation rate is an independent prognostic factor in Japanese patients with localized clear cell renal cell carcinoma. Urol Int 2009, 83:306-310.
28. Naya Y., Zenbutsu S., Araki K., et al. Influence of visceral obesity on oncologic outcome in patients with renal cell carcinoma. Urol Int 2010, 85:30-36.
29. Tierney J.F., Stewart L.A., Ghersi D., et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
30. Zwahlen M., Renehan A., Egger M. Meta-analysis in medical research: potentials and limitations. Urol Oncol 2008, 26:320-329.
31. Aggarwal B.B., Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients?. Curr Opin Pharmacol 2009, 9:351-369.
32. Roxburgh C.S., McMillan D.C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010, 6:149-163.
33. Tillett W.S., Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930, 52:561-571.
34. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
35. Koo A.S., Armstrong C., Bochner B., et al. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother 1992, 35:97-105.
36. Oya M., Takayanagi A., Horiguchi A., et al. Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 2003, 24:377-384.
37. Blay J.Y., Rossi J.F., Wijdenes, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997, 72:424-430.
38. Khera A., McGuire D.K., Murphy S.A., et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005, 46:464-469.